💊Merck’s Keytruda Misses Primary End Point for Gastric Cancer.
Merck MRK announced disappointing results from a pivotal phase III KEYNOTE-061 study, evaluating its anti-PD-1 therapy, Keytruda (pembrolizumab), as a second-line treatment for patients with advanced gastric or gastroesophageal junction (“GEJ”) adenocarcinoma.
Notably, Keytruda is already approved in the United States as a monotherapy for third-line treatment of advanced gastric or GEJ. Additionally, it is approved for many types of cancers and treatment settings including lung cancer, melanoma, head and neck cancer, classical hodgkin lymphoma and bladder cancer.
December 15, 2017 – Zacks.com
Merck Provides Update on KEYNOTE-061, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Gastric or Gastroesophageal Junction Adenocarcinoma | Merck Newsroom Home